SCHEMBL10140720

SCHEMBL10140720

[C-]#[N+]c1ccc2[nH]c(-c3c(O)c(-c4ccc(-c5ccccc5)cc4)nn3C)nc2c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDPK1 O15530 1/20 0.39
CDK4 P11802 3/20 0.39
CCNA2 P20248 3/20 0.39
CCND1 P24385 3/20 0.39
CDK2 P24941 3/20 0.39
CCND3 P30281 3/20 0.39
CA12 O43570 2/20 0.39
CA9 Q16790 2/20 0.39
P2RY6 Q15077 1/20 0.38
NPC1 O15118 5/20 0.36
RAB9A P51151 5/20 0.36
GAA P10253 1/20 0.36
JAK2 O60674 1/20 0.36
JAK1 P23458 1/20 0.36
TYK2 P29597 1/20 0.36
JAK3 P52333 1/20 0.36
CNR1 P21554 1/20 0.36
CNR2 P34972 1/20 0.36
GPR55 Q9Y2T6 1/20 0.36
KDR P35968 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10140741 0.90 KDM4E (0.42) PDPK1NPC1RAB9ASMN1; SMN2MAPT
SCHEMBL10140703 0.90 CA12 (0.39) PDPK1CDK4CCNA2CCND1CDK2
SCHEMBL10140793 0.89 F9 (0.41) CDK4CCNA2CCND1CDK2CCND3
SCHEMBL10140724 0.86 CA12 (0.40) PDPK1CDK4CCNA2CCND1CDK2
SCHEMBL10140767 0.84 NPC1 (0.43) PDPK1CDK4CCNA2CCND1CDK2
SCHEMBL7970842 0.82 NPC1 (0.55) CA12CA9P2RY6NPC1RAB9A
SCHEMBL10173220 0.81 CHEK2 (0.43) CDK4CCNA2CCND1CDK2CCND3
SCHEMBL10140455 0.81 AMY1A (0.44) CA12CA9NPC1RAB9AGAA
SCHEMBL10140728 0.80 F10 (0.53)
SCHEMBL10140918 0.80 F10 (0.37) CDK2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8148363-B2 Heterocyclic compounds as factor IXA inhibitors SCHERING CORPORATION (US) 2012-04-03 US disclosed
US-20110065682-A1 HETEROCYCLIC COMPOUNDS AS FACTOR IXA INHIBITORS MERCK SHARP & DOHME LLC 2011-03-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065682-A1 HETEROCYCLIC COMPOUNDS AS FACTOR IXA INHIBITORS F9, F12, F8 PDPK1 3623/4885CDK4 3342/4885CCNA2 2695/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.